Archives of neurology · 2006
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Allen Jeffrey A, Adlakha Ashish, Bergethon Peter R
Аннотация
OBJECTIVE: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.
DESIGN: Case report/literature review.
SETTING: University hospital.
PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
RESULTS: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.
CONCLUSIONS: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.
DESIGN: Case report/literature review.
SETTING: University hospital.
PATIENT: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.
RESULTS: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.
CONCLUSIONS: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.
Предметные рубрики MeSH
Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAphasiaBevacizumabBlindness, CorticalBlood VesselsCamptothecinCarcinomaCognition DisordersColonic NeoplasmsDementia, VascularFluorouracilHumansLeucovorinLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeovascularization, PathologicOccipital LobeParietal LobeVascular Endothelial Growth Factor A